- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CCL17/ A-152E5.3/ ABCD-2 functional antibody
Anti-CCL17/ A-152E5.3/ ABCD-2 functional antibody for cell culture, ELISA & in-vivo assay
Go to CCL17/CCL17 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE0742-Ab-1/ GM-Tg-hg-SE0742-Ab-2 | Anti-Human CCL17 monoclonal antibody | Human |
| GM-Tg-rg-SE0742-Ab-1/ GM-Tg-rg-SE0742-Ab-2 | Anti-Rat CCL17 monoclonal antibody | Rat |
| GM-Tg-mg-SE0742-Ab-1/ GM-Tg-mg-SE0742-Ab-2 | Anti-Mouse CCL17 monoclonal antibody | Mouse |
| GM-Tg-cynog-SE0742-Ab-1/ GM-Tg-cynog-SE0742-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CCL17 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE0742-Ab-1/ GM-Tg-felg-SE0742-Ab-2 | Anti-Feline CCL17 monoclonal antibody | Feline |
| GM-Tg-cang-SE0742-Ab-1/ GM-Tg-cang-SE0742-Ab-2 | Anti-Canine CCL17 monoclonal antibody | Canine |
| GM-Tg-bovg-SE0742-Ab-1/ GM-Tg-bovg-SE0742-Ab-2 | Anti-Bovine CCL17 monoclonal antibody | Bovine |
| GM-Tg-equg-SE0742-Ab-1/ GM-Tg-equg-SE0742-Ab-2 | Anti-Equine CCL17 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-SE0742-Ab-1/ GM-Tg-hg-SE0742-Ab-2; GM-Tg-rg-SE0742-Ab-1/ GM-Tg-rg-SE0742-Ab-2; GM-Tg-mg-SE0742-Ab-1/ GM-Tg-mg-SE0742-Ab-2; GM-Tg-cynog-SE0742-Ab-1/ GM-Tg-cynog-SE0742-Ab-2; GM-Tg-felg-SE0742-Ab-1/ GM-Tg-felg-SE0742-Ab-2; GM-Tg-cang-SE0742-Ab-1/ GM-Tg-cang-SE0742-Ab-2; GM-Tg-bovg-SE0742-Ab-1/ GM-Tg-bovg-SE0742-Ab-2; GM-Tg-equg-SE0742-Ab-1/ GM-Tg-equg-SE0742-Ab-2 |
| Products Name | Anti-CCL17 monoclonal antibody |
| Format | mab |
| Target Name | CCL17 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CCL17 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-SE0742-Ag-1 | Recombinant multi-species CCL17/ A-152E5.3/ ABCD-2 protein |
| Cytokine | GM-Tg-g-SE0742-Ag-1 | chemokine (C-C motif) ligand 17 (CCL17) protein |
| ORF Viral Vector | vGMLP004761 | human CCL17 Lentivirus particle |
| ORF Viral Vector | pGMLP004761 | human CCL17 Lentivirus plasmid |
| ORF Viral Vector | pGMLPm001036 | mouse Ccl17 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001036 | mouse Ccl17 Lentivirus particle |
Target information
| Target ID | GM-SE0742 |
| Target Name | CCL17 |
| Gene ID | 6361,20295,117518,574180,403586,493832,100140488,100630824 |
| Gene Symbol and Synonyms | A-152E5.3,ABCD-2,CCL17,SCYA17,Scya17l,TARC |
| Uniprot Accession | Q92583,Q9ERE0,Q8HYP9,Q95N01,Q8I021 |
| Uniprot Entry Name | CCL17_HUMAN,CCL17_MACMU,Q9ERE0_RAT,CCL17_FELCA,CCL17_CANLF |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Cytokine Target |
| Disease | Breast Cancer, Overactive bladder |
| Gene Ensembl | ENSG00000102970 |
| Target Classification | N/A |
The target: CCL17, gene name: CCL17, also named as A-152E5.3, ABCD-2, SCYA17, TARC. This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for T lymphocytes, but not monocytes or granulocytes. The product of this gene binds to chemokine receptors CCR4 and CCR8. This chemokine plays important roles in T cell development in thymus as well as in trafficking and activation of mature T cells. [provided by RefSeq, Sep 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
